CCL3 Promotes Proliferation of Colorectal Cancer

Xiaoliang Xie,Jinda Su,Yaqin He,Xiaoliang Yang,Sifan Zhai,Shikuo Rong,Xin Zhang,Fahai Gong,Geenyuan Peng,Hai Li,Guangxian Xu

DOI: https://doi.org/10.21203/rs.3.rs-963663/v1

2021-10-26

Abstract:Abstract Background: Chemokines and their receptors can be expressed on the surface of inflammatory cells and malignant tumor cells in the body. Tumor cells can participate in directional organ metastasis by means of the ‘navigation effect’ of chemokines. Recent studies have found that chemokine C-C motif chemokine ligand 3 (CCL3) plays an important role in the invasion and metastasis of malignant tumors. Determining the effect of chemokine CCL3 and the related cytokine network on colorectal cancer is helpful in developing new therapeutic targets and anti-tumor drugs, as well as improving the survival rate of patients. Methods: In this study, protein chip technology was used to examine colorectal cancer tissue samples and identify the key factors of chemokine CCL3 and the toll-like receptors/nuclear factor-κB (TLR/NF-κB) pathway in cancer and metastatic lymph nodes. In addition, we used lentiviral vector technology for transfection to construct interference and overexpression cell lines. The aim of this experiment was to analyze the mechanism of CCL3 and TNF receptor associated factor 6 (TRAF6)/NF-κB pathway-related factors and their effect on the proliferation of colon cancer cells. Finally, the expression and significance of CCL3 in colorectal cancer tissues and its correlation with clinical pathology were studied by immunohistochemistry. Results: The results confirmed that CCL3 and C-C motif chemokine receptor 5 (CCR5) were expressed in adjacent tissues, colorectal cancer tissues, and metastatic cancer. The expression level was correlated with clinical stage and nerve invasion. Conclusions: The expression of chemokine CCL3 and receptor CCR5 was positively correlated with the expression of TRAF6 and NF-κB, and could promote the proliferation, invasion, and migration of colorectal cancer cells through TRAF6 and NF-κB.